| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9004833 | Biomedicine & Pharmacotherapy | 2005 | 4 Pages |
Abstract
Conclusions. - Epirubicin-based chemotherapy causes an early increase of the QT and QTc dispersion, which is attenuated by dexrazoxane supplementation. Therefore, dexrazoxane can reduce the arrhythmic risk in patients treated with epirubicin.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Fabio Galetta, Ferdinando Franzoni, Giulia Cervetti, Nadia Cecconi, Angelo Carpi, Mario Petrini, Gino Santoro,